ArticleNeurology2017
Disease progression in
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.Brain imaging and behavior · 2021Pooled it
- Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis.Journal of neurology · 2020Pooled it
- Recalibration of the Frontal Behavioural Inventory Cut-Off for Behavioural Screening in Amyotrophic Lateral Sclerosis.European journal of neurology · 2026Article
- Mapping motor and extra-motor gray and white matter changes in ALS: a comprehensive review of MRI insights.Neuroradiology · 2025Review
- Predictors of Care Home Admission and Survival Rate in Patients With Syndromes Associated With Frontotemporal Lobar Degeneration in Europe.Neurology · 2024Observational
- Self-perceived quality of life, cognitive and behavioural impairment in amyotrophic lateral sclerosis.Journal of neurology · 2024Observational
- The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.Frontiers in aging neuroscience · 2024Article
- Brainstem-cortex disconnection in amyotrophic lateral sclerosis: bulbar impairment, genotype associations, asymptomatic changes and biomarker opportunities.Journal of neurology · 2023Article
- The landscape of cognitive impairment in superoxide dismutase 1-amyotrophic lateral sclerosis.Neural regeneration research · 2023Review
- Behavioral and Cognitive Phenotypes of Patients With Amyotrophic Lateral Sclerosis Carrying SOD1 Variants.Neurology · 2022Article
- Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.Alzheimer's research & therapy · 2022Article
- Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials.Journal of neuromuscular diseases · 2022Review
- Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD.Brain imaging and behavior · 2021Article
- Longitudinal changes in network homogeneity in presymptomatic C9orf72 mutation carriers.Neurobiology of aging · 2021Article
- Segmental involvement of the corpus callosum inTherapeutic advances in chronic disease · 2021Article
- Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.PloS one · 2021Article
- Electrical impedance myography (EIM) in a natural history study ofAmyotrophic lateral sclerosis & frontotemporal degeneration · 2020Article
- Motor function decline correlates with behavioral impairment inNeurology · 2020Article
- Resting State Functional Connectivity Is Decreased Globally Across theFrontiers in neurology · 2020Article
- A Healthy Heart and a Healthy Brain: Looking at Mitophagy.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in
methodsThirty-four unrelated participants with mutations in
resultsThe clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up.
conclusionsThe pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.